1. Clinical Overview
Desonide is a low-potency synthetic non-fluorinated corticosteroid used topically for its anti-inflammatory, antipruritic, and vasoconstrictive properties. The 0.05% w/w concentration is a common strength for dermatological use.
| Onset | Duration | Bioavailability |
|---|---|---|
| NA | NA | NA |
2. Mechanism of Action
Desonide acts by diffusing across cell membranes and binding with high affinity to specific cytoplasmic glucocorticoid receptors. This drug-receptor complex translocates to the cell nucleus, binds to DNA, and modifies gene transcription. This leads to the synthesis of anti-inflammatory proteins (lipocortins) and inhibition of the synthesis of pro-inflammatory mediators such as prostaglandins and leukotrienes by blocking phospholipase A2. It also inhibits the release of histamine from mast cells, reduces capillary permeability and vasodilation, and suppresses migration of polymorphonuclear leukocytes and fibroblasts, resulting in reduced inflammation, pruritus, and epidermal proliferation.
3. Indications & Uses
- Atopic dermatitis (eczema)
- Seborrheic dermatitis
- Contact dermatitis (allergic and irritant)
- Psoriasis (mild to moderate)
- Intertrigo
- Pruritus associated with inflammatory skin conditions
- Diaper rash (in specific formulations)
4. Dosage & Administration
Adult Dosage: Apply a thin film to the affected area 2 to 3 times daily. Therapy should be limited to 2-4 weeks.
Administration: Clean and dry the affected area before application. Apply a thin layer and rub gently. Wash hands after application unless hands are the treated area. Do not cover with occlusive dressings unless directed by a physician. Avoid use on large surface areas, under diapers, or on broken skin unless specifically indicated.
5. Side Effects
Common side effects may include:
- Local burning or stinging at application site
- Pruritus (itching)
- Dryness of skin
- Erythema (redness)
- Skin irritation
- Folliculitis
- Allergic contact dermatitis
- Skin atrophy with prolonged use
- Telangiectasia (visible blood vessels) with prolonged use
- Striae (stretch marks) with prolonged use
- Hypopigmentation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other topical corticosteroids | Increased risk of additive systemic absorption and local adverse effects (atrophy, striae). | Moderate |
| Topical immunosuppressants (e.g., Tacrolimus, Pimecrolimus) | Concomitant use may increase risk of local immunosuppression and infection. Sequential use is common in therapy. | Moderate |
| Occlusive dressings or wraps | Markedly increases percutaneous absorption, raising the risk of systemic corticosteroid effects and local adverse reactions. | High |
7. Patient Counselling
8. Toxicology & Storage
Overdose: Seek immediate medical attention.
Storage: Store in a cool, dry place.